Optimizing management of hirudin anticoagulation

Area of Science:

• Cardiovascular Medicine
• Biomedical Engineering
• Clinical Chemistry

Background:

• Accurate anticoagulation monitoring is essential during cardiac surgery (CS), particularly for direct thrombin inhibitors like bivalirudin, which lack specific antidotes.
• The standard activated clotting time (ACT) assay shows reduced sensitivity at high bivalirudin concentrations, limiting its utility in CS.
• Existing assays struggle to monitor therapeutic levels of novel anticoagulants required for complex procedures.

Purpose of the Study:

• To develop and evaluate a novel assay, the ACTT, designed for enhanced linear sensitivity to bivalirudin at concentrations relevant to cardiac surgery.
• To compare the performance of the ACTT assay against the standard ACT+ assay for bivalirudin monitoring in vitro and ex vivo.

Main Methods:

• Development of the ACTT assay to improve sensitivity in the 15-30 microg/mL bivalirubin range.
• In vitro studies comparing ACTT and ACT+ clotting times across varying bivalirudin concentrations.
• Ex vivo evaluation of the ACTT assay in 67 patients undergoing percutaneous cardiac intervention (PCI), comparing results with the ACT+ assay.

Main Results:

• The ACTT assay demonstrated excellent linearity and superior reproducibility (CV <15%) for bivalirudin concentrations up to 30 microg/mL.
• In vitro, ACTT and ACT+ clotting times diverged significantly around 10 microg/mL bivalirudin.
• Ex vivo patient data showed good agreement between ACTT and ACT+ at lower clotting times, with ACTT exhibiting increased sensitivity at higher levels.

Conclusions:

• The ACTT assay provides increased sensitivity to high levels of bivalirudin compared to the standard ACT+ assay.
• The ACTT assay shows potential for accurate anticoagulation monitoring of bivalirudin during cardiac surgery.
• This novel assay could improve the safety and efficacy of direct thrombin inhibitor use in cardiovascular procedures.